Modeling tumor volume trajectory and outcome identifies three distinct response classes in lower-grade IDH-mutant glioma receiving first-line chemotherapy
Clicks: 3
ID: 321005
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #90 of 105 articles by views in Neuro-Oncology Advances
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Isocitrate Dehydrogenase (IDH)-mutant gliomas are infiltrative brain tumors with heterogeneous clinical courses. Predicting individual responses to chemotherapy and long-term outcomes remains challenging. We aimed to characterize distinct patterns of tumor evolution during first-line chemotherapy using longitudinal tumor volume dynamics and clinical outcomes. Methods We retrospectively included 195 patients treated at a single institution and analyzed 1,956 MRI examinations obtained during chemotherapy. Tumor volume and mean tumor diameter (MTD) were quantified on T2/FLAIR-weighted images using an automated nnU-Net-based segmentation algorithm. Tumor evolution was analyzed using latent class joint models integrating longitudinal tumor measurements and time-to-event outcomes. Results Modeling based on MTD trajectories and overall survival (OS) identified three distinct response classes. The non-response class (13.8%) was characterized by early tumor growth from treatment initiation and poor outcomes (median progression-free survival [PFS]: 8.1 months; median time to anaplastic transformation [TAT]: 19.9 months; median OS: 41.1 months). The durable response class (57.4%) showed stable or slightly decreasing MTD trajectories and favorable outcomes (median PFS: 73.2 months; median TAT: 93.2 months; median OS: 169.3 months). Conversely, the transient response class (28.7%) exhibited an initial decrease in tumor size followed by rapid regrowth within two years (median PFS: 31.4 months; median TAT: 27.9 months; median OS: 54.2 months). Conclusions Longitudinal modeling of MTD trajectories together with OS identified clinically meaningful chemotherapy response patterns in IDH-mutant gliomas, strongly associated with progression and malignant transformation. While most patients exhibited durable responses, others showed unfavorable trajectories, highlighting the need for early biomarkers to tailor treatment strategies.
| Reference Key |
openalex_W7168256123
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Amélie Darlix, Eva Teruel, Aude Trinquet, Emmanuelle Le Bars, Hugues Duffau, Sam Ng, Valérie Rigau, Marie-Sophie Duc, Mathilde Carrière, Jérémy Deverdun |
| Journal | Neuro-Oncology Advances |
| Year | 2026 |
| DOI |
10.1093/noajnl/vdag183
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.